leukemia: Bone marrow transplantation for leukemia and multi-state...
In BART: Bayesian Additive Regression Trees

leukemia

R Documentation

Bone marrow transplantation for leukemia and multi-state models

Description

137 patients with acute myelocytic leukemia (AML) and acute lymphoblastic leukemia (ALL) were given oral busulfan (Bu) 4 mg/kg on each of 4 days and intravenous cyclophosphamide (Cy) 60 mg/kg on each of 2 days (BuCy2) followed by allogeneic bone marrow transplantation from an HLA-identical or one antigen disparate sibling.

Usage

data(leukemia)

Format

A data frame with 137 subjects on the following 22 variables.

G: Disease Group (1=ALL, 2=AML Low Risk in first remission, 3=AML High Risk not in first remission)
TD: Time To Death Or On Study Time
TB: Disease Free Survival Time (Time To Relapse, Death Or End Of Study)
D: Death Indicator (0=Alive, 1=Dead)
R: Relapse Indicator (0=Disease Free, 1=Relapsed)
B: Disease Free Survival Indicator (0=Alive and Disease Free, 1=Dead or Relapsed)
TA: Time To Acute Graft-Versus-Host Disease (GVHD)
A: Acute GVHD Indicator (0=Never Developed Acute GVHD, 1=Developed Acute GVHD)
TC: Time To Chronic Graft-Versus-Host Disease (GVHD)
C: Chronic GVHD Indicator (0=Never Developed Chronic GVHD, 1=Developed Chronic GVHD)
TP: Time of Platelets Returning to Normal Levels
P: Platelet Recovery Indicator (0=Platelets Never Returned to Normal, 1=Platelets Returned To Normal)
X1: Patient Age In Years
X2: Donor Age In Years
X3: Patient Gender (0=female, 1=male)
X4: Donor Gender (0=female, 1=male)
X5: Patient Cytomegalovirus (CMV) Immune Status (0=CMV Negative, 1=CMV Positive)
X6: Donor Cytomegalovirus (CMV) Immune Status (0=CMV Negative, 1=CMV Positive)
X7: Waiting Time to Transplant In Days
X8: AML Patients with Elevated Risk By French-American-British (FAB) Classification (0=Not AML/Elevated, 1=FAB M4 Or M5 with AML)
X9: Hospital (1=The Ohio State University in Columbus, 2=Alfred in Melbourne, 3=St. Vincent in Sydney, 4=Hahnemann University in Philadelphia)
X10: Methotrexate Used as a Graft-Versus-Host Disease Prophylactic (0=No, 1=Yes)

Source

Klein J. and Moeschberger M.L. (2003) Survival Analysis: Techniques for Censored and Truncated Data, New York: Springer-Verlag, 2nd Ed., Section 1.3. https://www.mcw.edu/-/media/MCW/Departments/Biostatistics/datafromsection13.txt

References

Copelan E., Biggs J., Thompson J., Crilley P., Szer J., Klein, J., Kapoor N., Avalos, B., Cunningham I. and Atkinson, K. (1991) "Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2". Blood, 78(3), pp.838-843.

BART documentation built on March 31, 2023, 5:17 p.m.